focus -WSS

focus

author：focus 2025-09-30 03:50:56 Page View：853

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

The blockbuster weight loss and diabetes drug sold by Eli Lilly also appears to improve fatty liver disease, according to early clinical trial data the pharmaceutical company released Tuesday.

Eli Lilly reported during its fourth-quarter earnings call that tirzepatide, which is sold commercially as Mounjaro or Zepbound, succeeded in a Phase 2 test as a treatment for the liver disease MASH. Around 74% of adults in the trial taking the drug were free of MASH after 52 weeks, compared to approximately 13% of the placebo group.

MASH, formerly known as NASH, is a liver disease characterized by excess fat and inflammation. The chronic inflammation can also lead to liver scarring, or fibrosis.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Stem cell treatment guidelines are released by FDA
Next article： After affirmative action ruling, medical educators look to 'holistic review'

knowledge

Hepatitis C has a cure — but many Americans still lack access to it

AdobeIn2005,NickVoyleswasdiagnosedwithhepatitisCafterbeingreleasedfromfiveyearsofincarceration.Anurs

Covid hospitalizations on the rise, Humana says

MoreolderadultshavebeenhospitalizedforCovid-19overthepastseveralweeks,accordingtodatareviewedbyhealt

Medical leaders decry Supreme Court decision on affirmative action

STEFANIREYNOLDS/AFPviaGettyImagesMedicalleadersonThursdayreactedswiftlytotheSupremeCourt’sdecisionto

How to fix cancer clinical trials' diversity problem

Clockwisefromtopleft:STAT'sNicholasSt.Fleur(moderator);JudySewards,headofclinicaltrialexperienceatPf

focus

Wikipedia

knowledge

How to fix cancer clinical trials' diversity problem